Michael Matthay, MD

PROF IN RES-HCOMP

Pulmonary, Critical Care, Allergy and Sleep Medicine

Dr. Matthay's overall focus is on improving clinical care of patients with acute respiratory failure from the acute respiratory distress syndrome and from sepsis. His research and clinical trials groups are very well funded by grants from the National Institute of Health. He also spends considerable time mentoring physicians and young faculty in career development and academic medicine.

Education
Fellowship, 1979 - Cardiovascular Research Institute, University of California, San Francisco
Fellowship, 1978 - Pulmonary DIvision, University of California, San Francisco
Internship and Residency, 1976 - Internal Medicine, University of Colorado Medical Center
M.D., 1973 - School of Medicine, University of Pennsylvania
A.B., 1969 - English, Harvard University
Honors and Awards
  • Edward Livingston Trudeau Medal, American Thoracic Society, 2014
  • Lifetime Achievement in Mentoring Award, University of California, San Francisco, 2013
  • Honora Causa, University of Paris, 2011
  • Julius Comroe, Jr. Award, American Physiologic Society, 2009
  • Trudeau Award, New York State Thoracic Society, 2009
  • Roger Bone Memorial Lecture, American College of Chest Physicians, 2006
  • Distinguished Clinical Research Lecture, University of California, San Francisco, 2006
  • Scientific Achievement Award, American Thoracic Society, 2002
  • Elected Member, American Association of Physicians, 2001
  • Elected Member, Western Association of Physicians, 1995
  • Henry Christian Award for Excellence in Research, AFCR, 1991
  • Elected Senior Member, Scientific Staff, Cardiovascular Research Institute, UCSF, 1989
  • Elected Member, American Physiologic Society, 1986
  • Elected Associate Member, Scientific Staff, Cardiovascular Research Institute, UCSF, 1984
  • Outstanding Student in Clinical Medicine, University of Pennsylvania School of Medicine, 1973
Websites
Publications
  1. Gli1+ mesenchymal stromal cells form a pathological niche to promote airway progenitor metaplasia in the fibrotic lung.
  2. Using Best Subsets Regression to Identify Clinical Characteristics and Biomarkers Associated with Sepsis-Associated Acute Kidney Injury.
  3. Proinflammatory cytokines and ARDS pulmonary edema fluid induce CD40 on human mesenchymal stromal cells-A potential mechanism for immune modulation.
  4. Biological Mechanisms of COVID-19 ARDS.
  5. Corticosteroids, COVID-19 pneumonia and acute respiratory distress syndrome.
  6. The endogenous capacity to produce proinflammatory mediators by the ex vivo human perfused lung.
  7. The ABO Histo-Blood Group, endothelial activation, and acute respiratory distress syndrome risk in critical illness.
  8. Insufficient hyperfibrinolysis in COVID-19: a systematic review of thrombolysis based on meta-analysis and meta-regression.
  9. Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells.
  10. NT-proBNP levels in the identification and classification of pulmonary transfusion reactions.
  11. Dose-Dependent Pulmonary Toxicity of Aerosolized Vitamin E Acetate.
  12. Need for Additional Trials of Vitamin C for Sepsis.
  13. Combined Mesenchymal Stromal Cell Therapy and ECMO in ARDS: A Controlled Experimental Study in Sheep.
  14. Association of patient weight status with plasma surfactant protein D, a biomarker of alveolar epithelial injury, in children with acute respiratory failure.
  15. Higher plasma cystatin C is associated with mortality after acute respiratory distress syndrome: findings from a Fluid and Catheter Treatment Trial (FACTT) substudy.
  16. Extracellular Vesicles: A New Frontier for Research in Acute Respiratory Distress Syndrome.
  17. Is a "Cytokine Storm" Relevant to COVID-19?
  18. THE EX-VIVO PERFUSED HUMAN LUNG IS RESISTANT TO INJURY BY HIGH-DOSE S. PNEUMONIAE BACTEREMIA.
  19. Clinician Recognition of the Acute Respiratory Distress Syndrome: Risk Factors for Under-Recognition and Trends Over Time.
  20. Impact of Bilateral Infiltrates on Inflammatory Biomarker Levels and Clinical Outcomes of Children With Oxygenation Defect.
  21. Plasmin improves blood-gas barrier function in oedematous lungs by cleaving epithelial sodium channels.
  22. Monitoring Research Blood Sampling in Critically Ill Patients: Avoiding Iatrogenic Anemia.
  23. Patterns and Trends in Advance Care Planning Among Older Adults Who Received Intensive Care at the End of Life.
  24. The potential of lipid mediator networks as ocular surface therapeutics and biomarkers.
  25. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis.
  26. Surfactant Protein D is Associated with Severe Pediatric Acute Respiratory Distress Syndrome, Prolonged Ventilation, and Death in Children with Acute Respiratory Failure.
  27. Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models: protocol for a systematic review and meta-analysis.
  28. Gender Differences in Authorship of Critical Care Literature.
  29. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility.
  30. Acute respiratory distress syndrome-attributable mortality in critically ill patients with sepsis.
  31. Treatment for severe acute respiratory distress syndrome from COVID-19.
  32. Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care: NHLBI Working Group Report.
  33. Improved survival after lung transplantation for adults requiring preoperative invasive mechanical ventilation: A national cohort study.
  34. Potential Value of Biomarker Signatures in Sepsis and Acute Respiratory Distress Syndrome in Children and Adults.
  35. Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop.
  36. Time to Recognition of Sepsis in the Emergency Department Using Electronic Health Record Data: A Comparative Analysis of Systemic Inflammatory Response Syndrome, Sequential Organ Failure Assessment, and Quick Sequential Organ Failure Assessment.
  37. Peripheral Blood Leukocyte Telomere Length is Associated with Survival of Sepsis Patients.
  38. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.
  39. Plasma sRAGE Acts as Genetically Regulated Causal Intermediate in Sepsis-Associated ARDS.
  40. The authors reply.
  41. Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study.
  42. The value of kinetic glomerular filtration rate estimation on medication dosing in acute kidney injury.
  43. Therapeutic Effects of Hyaluronic Acid in Bacterial Pneumonia in the Ex Vivo Perfused Human Lungs.
  44. Proliferative regulation of alveolar epithelial type 2 progenitor cells by human Scnn1d gene.
  45. Lung Inflammatory Environments Differentially Alter Mesenchymal Stromal Cell Behavior.
  46. Clinically Relevant Model of Pneumococcal Pneumonia, ARDS, and Non-Pulmonary Organ Dysfunction in Mice.
  47. Plasma total fibroblast growth factor 23 levels are associated with acute kidney injury and mortality in children with acute respiratory distress syndrome.
  48. A Multicenter Study of the Causes and Consequences of Optimistic Expectations About Prognosis by Surrogate Decision-Makers in ICUs.
  49. Association of Elevated Plasma Interleukin 18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome.
  50. The Continued Need for Clinical Trials in Deceased Organ Donor Management.
  51. The ex vivo human lung: research value for translational science.
  52. Pulmonary Dead Space Monitoring: Identifying Subjects With ARDS at Risk of Developing Right Ventricular Dysfunction.
  53. Pathogenesis of Acute Respiratory Distress Syndrome.
  54. Clinician-Family Communication About Patients' Values and Preferences in Intensive Care Units.
  55. Is a Part Better than the Whole for Cell-based Therapy for Acute Respiratory Distress Syndrome?
  56. A prospective investigation of interleukin-8 levels in pediatric acute respiratory failure and acute respiratory distress syndrome.
  57. Could Decisions to Limit Treatment Contribute to Mortality Differences between Patients with Different Presepsis Trajectories?
  58. Identification of Acute Kidney Injury Subphenotypes with Differing Molecular Signatures and Responses to Vasopressin Therapy.
  59. Positive Cumulative Fluid Balance Is Associated With Mortality in Pediatric Acute Respiratory Distress Syndrome in the Setting of Acute Kidney Injury.
  60. Precision medicine for cell therapy in acute respiratory distress syndrome - Authors' reply.
  61. The authors reply.
  62. The authors reply.
  63. Acute respiratory distress syndrome.
  64. Heterogeneity in sepsis: new biological evidence with clinical applications.
  65. AIMing Immunomodulation Therapy at Sepsis.
  66. Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure.
  67. Physiologic Analysis and Clinical Performance of the Ventilatory Ratio in Acute Respiratory Distress Syndrome.
  68. Early Plasma Matrix Metalloproteinase Profiles. A Novel Pathway in Pediatric Acute Respiratory Distress Syndrome.
  69. ECMO in severe acute respiratory distress syndrome.
  70. Low to Moderate Air Pollutant Exposure and Acute Respiratory Distress Syndrome after Severe Trauma.
  71. Variability in Pediatric Ideal Body Weight Calculation: Implications for Lung-Protective Mechanical Ventilation Strategies in Pediatric Acute Respiratory Distress Syndrome.
  72. Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults.
  73. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
  74. Beyond Low Tidal Volume Ventilation: Treatment Adjuncts for Severe Respiratory Failure in Acute Respiratory Distress Syndrome.
  75. Therapeutic potential of mesenchymal stromal cells in the treatment of ARDS.
  76. Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis.
  77. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study.
  78. Interleukin-1 Receptor Antagonist Is Associated With Pediatric Acute Respiratory Distress Syndrome and Worse Outcomes in Children With Acute Respiratory Failure.
  79. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.
  80. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
  81. Possible hepatotoxicity of IQOS.
  82. Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury.
  83. Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia.
  84. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.
  85. Effect of Rosuvastatin on Acute Kidney Injury in Sepsis-Associated Acute Respiratory Distress Syndrome.
  86. Effects of bone marrow-derived mesenchymal stromal cells on gene expression in human alveolar type II cells exposed to TNF-a, IL-1ß, and IFN-?.
  87. Pulmonary mechanics and gas exchange characteristics in uncommon etiologies of acute respiratory distress syndrome.
  88. Plasma sRAGE is independently associated with increased mortality in ARDS: a meta-analysis of individual patient data.
  89. Human pulmonary endothelial cell permeability after exposure to LPS-stimulated leukocyte supernatants derived from patients with early sepsis.
  90. Expansion of hedgehog disrupts mesenchymal identity and induces emphysema phenotype.
  91. Influence of Clinical Factors and Exclusion Criteria on Mortality in ARDS Observational Studies and Randomized Controlled Trials.
  92. A psychometric study of the decisional conflict scale in surrogate decision makers.
  93. Secondary peritonitis: principles of diagnosis and intervention.
  94. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS.
  95. Mesenchymal stromal cells and macrophages in sepsis: new insights.
  96. Contemporary Risk Factors and Outcomes of Transfusion-Associated Circulatory Overload.
  97. Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS.
  98. Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice.
  99. Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.
  100. Assessing Preventable Harms in the Intensive Care Unit: Data From a Tertiary Care Academic Medical Institution.
  101. Elevated donor plasminogen activator inhibitor-1 levels and the risk of primary graft dysfunction.
  102. The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia.
  103. Cell-based Therapy in Sepsis. A Step Closer.
  104. Mesenchymal stem cell-derived extracellular vesicles attenuate pulmonary vascular permeability and lung injury induced by hemorrhagic shock and trauma.
  105. Exosome-based Therapy for Bronchopulmonary Dysplasia.
  106. Measurement of Protein Permeability and Fluid Transport of Human Alveolar Epithelial Type II Cells Under Pathological Conditions.
  107. Rectal and Bladder Temperatures vs Forehead Core Temperatures Measured With SpotOn Monitoring System.
  108. Clinical Presentation and Outcomes among Children with Sepsis Presenting to a Public Tertiary Hospital in Tanzania.
  109. The Epithelial Sodium Channel Is a Modifier of the Long-Term Nonprogressive Phenotype Associated with F508del CFTR Mutations.
  110. ENaCs as Both Effectors and Regulators of MiRNAs in Lung Epithelial Development and Regeneration.
  111. Extracellular Vesicle Transfer from Mesenchymal Stromal Cells Modulates Macrophage Function in Acute Lung Injury. Basic Science and Clinical Implications.
  112. Intratracheal instillation of alveolar type II cells enhances recovery from acute lung injury in rats.
  113. Cytokine Profiles of Severe Influenza Virus-Related Complications in Children.
  114. Reply to "Letter to the Editor: Pulmonary toxicity of electronic cigarettes: more doubts than certainties".
  115. Cigarette Smoke Exposure Worsens Endotoxin-Induced Lung Injury and Pulmonary Edema in Mice.
  116. Derivation and validation of a two-biomarker panel for diagnosis of ARDS in patients with severe traumatic injuries.
  117. Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value.
  118. Local lung hypoxia determines epithelial fate decisions during alveolar regeneration.
  119. Epithelial Sodium Channel-a Mediates the Protective Effect of the TNF-Derived TIP Peptide in Pneumolysin-Induced Endothelial Barrier Dysfunction.
  120. Effects of IV Acetaminophen on Core Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults: A Randomized Controlled Trial.
  121. Endothelial Damage During Septic Shock: Significance and Implications for Future Therapies.
  122. Inhalation therapies in acute respiratory distress syndrome.
  123. Lung Injury Etiology and Other Factors Influencing the Relationship Between Dead-Space Fraction and Mortality in ARDS.
  124. External validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome.
  125. Clinical trials in acute respiratory distress syndrome: challenges and opportunities.
  126. Pulmonary toxicity of e-cigarettes.
  127. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial.
  128. Erratum to: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction - a randomised placebo-controlled trial (KARE): study protocol.
  129. Understanding blood gas analysis.
  130. Differentiating pulmonary transfusion reactions using recipient and transfusion factors.
  131. Incorporating Inflammation into Mortality Risk in Pediatric Acute Respiratory Distress Syndrome.
  132. Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome.
  133. Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection.
  134. Signals of vagal circuits engaging with AKT1 in a7 nAChR+CD11b+ cells lessen E. coli and LPS-induced acute inflammatory injury.
  135. Alveolar Fluid Clearance in Pathologically Relevant Conditions: In Vitro and In Vivo Models of Acute Respiratory Distress Syndrome.
  136. Profiling of ARDS pulmonary edema fluid identifies a metabolically distinct subset.
  137. Higher mini-BAL total protein concentration in early ARDS predicts faster resolution of lung injury measured by more ventilator-free days.
  138. Protein biomarkers associated with primary graft dysfunction following lung transplantation.
  139. Concise Review: Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction Following Trauma or Sepsis.
  140. Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm.
  141. Acute kidney injury subphenotypes based on creatinine trajectory identifies patients at increased risk of death.
  142. Clinical, Radiographic, Physiologic, and Biologic Measurements to Facilitate Personalized Medicine for ARDS.
  143. Overnight Extubation in Patients With Mechanical Ventilation: Is It Harmful?
  144. What drives neutrophils to the alveoli in ARDS?
  145. Cathepsin L Helps to Defend Mice from Infection with Influenza A.
  146. Challenges in predicting which patients will develop ARDS.
  147. A Simple and Robust Bedside Model for Mortality Risk in Pediatric Patients With Acute Respiratory Distress Syndrome.
  148. Poor Adherence to Lung-Protective Mechanical Ventilation in Pediatric Acute Respiratory Distress Syndrome.
  149. IL1RL1 asthma risk variants regulate airway type 2 inflammation.
  150. Plasma Concentrations of Soluble Suppression of Tumorigenicity-2 and Interleukin-6 Are Predictive of Successful Liberation From Mechanical Ventilation in Patients With the Acute Respiratory Distress Syndrome.
  151. The authors reply.
  152. The authors reply.
  153. miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis.
  154. Quantifying unintended exposure to high tidal volumes from breath stacking dyssynchrony in ARDS: the BREATHE criteria.
  155. A new experimental model of acid- and endotoxin-induced acute lung injury in rats.
  156. The acute respiratory distress syndrome following isolated severe traumatic brain injury.
  157. Association of common genetic variation in the protein C pathway genes with clinical outcomes in acute respiratory distress syndrome.
  158. Sepsis: pathophysiology and clinical management.
  159. Long-Term Ozone Exposure Increases the Risk of Developing the Acute Respiratory Distress Syndrome.
  160. Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS.
  161. Negative-Pressure Pulmonary Edema.
  162. Experts' opinion on management of hemodynamics in ARDS patients: focus on the effects of mechanical ventilation.
  163. Diagnostic workup for ARDS patients.
  164. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo.
  165. Key stakeholders' perceptions of the acceptability and usefulness of a tablet-based tool to improve communication and shared decision making in ICUs.
  166. Acute Hypoxemic Respiratory Failure after Large-Volume Thoracentesis. Mechanisms of Pleural Fluid Formation and Reexpansion Pulmonary Edema.
  167. New Strategies for Effective Therapeutics in Critically Ill Patients.
  168. Cigarette smokers have exaggerated alveolar barrier disruption in response to lipopolysaccharide inhalation.
  169. Acute cor pulmonale and the acute respiratory distress syndrome.
  170. Timing of Intubation and Clinical Outcomes in Adults With Acute Respiratory Distress Syndrome.
  171. Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study.
  172. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality.
  173. Cigarette Smoke Exposure and the Acute Respiratory Distress Syndrome.
  174. Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice.
  175. Resolution of Alveolar Edema in Acute Respiratory Distress Syndrome. Physiology and Biology.
  176. Human Mesenchymal Stem (Stromal) Cells Promote the Resolution of Acute Lung Injury in Part through Lipoxin A4.
  177. Visualization of Fra-1/AP-1 activation during LPS-induced inflammatory lung injury using fluorescence optical imaging.
  178. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies.
  179. Unexpected Role for Adaptive aßTh17 Cells in Acute Respiratory Distress Syndrome.
  180. Saving lives with high-flow nasal oxygen.
  181. Sedation protocol for critically ill pediatric patients--reply.
  182. Estimating dead-space fraction for secondary analyses of acute respiratory distress syndrome clinical trials.
  183. Microvesicles Derived From Human Mesenchymal Stem Cells Restore Alveolar Fluid Clearance in Human Lungs Rejected for Transplantation.
  184. Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome - authors' reply.
  185. Increased expression of neutrophil-related genes in patients with early sepsis-induced ARDS.
  186. Erratum to: plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome.
  187. Therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome.
  188. Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions.
  189. Plasma soluble thrombomodulin levels are associated with mortality in the acute respiratory distress syndrome.
  190. A multicenter study of key stakeholders' perspectives on communicating with surrogates about prognosis in intensive care units.
  191. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial.
  192. Proteolytic regulation of epithelial sodium channels by urokinase plasminogen activator: cutting edge and cleavage sites.
  193. Body temperature and mortality in patients with acute respiratory distress syndrome.
  194. Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury.
  195. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
  196. Recipient clinical risk factors predominate in possible transfusion-related acute lung injury.
  197. Biology and pathology of fibroproliferation following the acute respiratory distress syndrome.
  198. Biomarkers to exclude the diagnosis of ventilator-associated pneumonia.
  199. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis.
  200. Endogenous and exogenous cell-based pathways for recovery from acute respiratory distress syndrome.
  201. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.
  202. A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation.
  203. Prevalence and impact of active and passive cigarette smoking in acute respiratory distress syndrome.
  204. Is there a need for emerging drugs for the acute respiratory distress syndrome?
  205. Donor smoking is associated with pulmonary edema, inflammation and epithelial dysfunction in ex vivo human donor lungs.
  206. Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.
  207. Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy.
  208. Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction.
  209. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome.
  210. Intensive care unit scoring systems outperform emergency department scoring systems for mortality prediction in critically ill patients: a prospective cohort study.
  211. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury*.
  212. Translational studies in the ex vivo human lung.
  213. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury.
  214. Accumulation of BDCA1? dendritic cells in interstitial fibrotic lung diseases and Th2-high asthma.
  215. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia.
  216. Resolution of pulmonary edema. Thirty years of progress.
  217. Correspondence to: soliciting strategies for developing cell-based reference materials to advance mesenchymal stem/stromal cell research and clinical translation.
  218. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.
  219. Rosuvastatin for sepsis-associated acute respiratory distress syndrome.
  220. Mechanical ventilation in acute hypoxemic respiratory failure: a review of new strategies for the practicing hospitalist.
  221. Applying metabolomics to uncover novel biology in ARDS.
  222. Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury.
  223. A randomized trial of the effects of nebulized albuterol on pulmonary edema in brain-dead organ donors.
  224. Is there still a role for the lung injury score in the era of the Berlin definition ARDS?
  225. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation.
  226. Mesenchymal stromal (stem) cell therapy: an emerging immunomodulatory strategy for the adjunctive treatment of sepsis.
  227. Metabolomic derangements are associated with mortality in critically ill adult patients.
  228. Reperfusion pulmonary edema in children with tetralogy of Fallot, pulmonary atresia, and major aortopulmonary collateral arteries undergoing unifocalization procedures: A pilot study examining potential pathophysiologic mechanisms and clinical significanc
  229. One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome.
  230. TGF-ß and lung fluid balance in ARDS.
  231. Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial.
  232. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice.
  233. The association between physiologic dead-space fraction and mortality in subjects with ARDS enrolled in a prospective multi-center clinical trial.
  234. Treating ARDS: new hope for a tough problem.
  235. Cystic fibrosis epithelial cell and bacterial binding.
  236. Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome.
  237. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome.
  238. Comparison of thermodilution measured extravascular lung water with chest radiographic assessment of pulmonary oedema in patients with acute lung injury.
  239. Viral pathogens and acute lung injury: investigations inspired by the SARS epidemic and the 2009 H1N1 influenza pandemic.
  240. Acute cor pulmonale in ARDS.
  241. Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.
  242. Early acute lung injury: criteria for identifying lung injury prior to the need for positive pressure ventilation*.
  243. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing.
  244. Reply: idiopathic pulmonary fibrosis: a degenerative disease requiring a regenerative approach.
  245. Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia.
  246. Cell therapy for lung disease: a step forward.
  247. The acute respiratory distress syndrome in 2013.
  248. HMGB1 accelerates alveolar epithelial repair via an IL-1ß- and avß6 integrin-dependent activation of TGF-ß1.
  249. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients.
  250. The Berlin definition of ARDS versus pathological evidence of diffuse alveolar damage.
  251. The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases.
  252. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria.
  253. Noradrenergic neurons regulate monocyte trafficking and mortality during gram-negative peritonitis in mice.
  254. Calcium flux and endothelial dysfunction during acute lung injury: a STIMulating target for therapy.
  255. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction--a randomised placebo-controlled trial (KARE): study protocol.
  256. Dysfunction of inflammation-resolving pathways is associated with exaggerated postoperative cognitive decline in a rat model of the metabolic syndrome.
  257. Activation of the heat shock response attenuates the interleukin 1ß-mediated inhibition of the amiloride-sensitive alveolar epithelial ion transport.
  258. Risk factors and outcomes in transfusion-associated circulatory overload.
  259. From protective ventilation to super-protective ventilation for acute respiratory distress syndrome.
  260. Cecal ligation model of sepsis in mice: new insights.
  261. Hyperoxic acute lung injury.
  262. Regulation and repair of the alveolar-capillary barrier in acute lung injury.
  263. IL-8 inhibits cAMP-stimulated alveolar epithelial fluid transport via a GRK2/PI3K-dependent mechanism.
  264. Novel aspects of urokinase function in the injured lung: role of a2-macroglobulin.
  265. Beta-adrenergic receptor polymorphisms and cardiac graft function in potential organ donors.
  266. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials.
  267. The acute respiratory distress syndrome.
  268. The severity of shock is associated with impaired rates of net alveolar fluid clearance in clinical acute lung injury.
  269. Clinical evidence of early acute lung injury often precedes the diagnosis of ALI.
  270. Clinical review: Early treatment of acute lung injury--paradigm shift toward prevention and treatment prior to respiratory failure.
  271. Inflection points in sepsis biology: from local defense to systemic organ injury.
  272. Cell-based therapy for acute lung injury: are we there yet?
  273. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance.
  274. The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats.
  275. Protein kinase C-a and arginase I mediate pneumolysin-induced pulmonary endothelial hyperpermeability.
  276. Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential.
  277. IQGAP1 is necessary for pulmonary vascular barrier protection in murine acute lung injury and pneumonia.
  278. Progress in modelling acute lung injury in a pre-clinical mouse model.
  279. Mesenchymal stem cells and the stem cell niche: a new chapter.
  280. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes.
  281. Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis.
  282. The 4G/4G genotype of the PAI-1 (serpine-1) 4G/5G polymorphism is associated with decreased lung allograft utilization.
  283. Quantifying the severity of acute lung injury using dead-space ventilation: should the lung injury score be updated?
  284. Comparison of chest radiograph scoring to lung weight as a quantitative index of pulmonary edema in organ donors.
  285. Anti-inflammatory effects of ß2 adrenergic receptor agonists in experimental acute lung injury.
  286. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma.
  287. Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema.
  288. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia.
  289. Altered lymphatics in an ovine model of congenital heart disease with increased pulmonary blood flow.
  290. The association between a Darc gene polymorphism and clinical outcomes in African American patients with acute lung injury.
  291. A simple classification model for hospital mortality in patients with acute lung injury managed with lung protective ventilation.
  292. Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes.
  293. Transfusion-related acute lung injury: incidence and risk factors.
  294. Prognostic value of pulmonary dead space in patients with the acute respiratory distress syndrome.
  295. Acute lung failure.
  296. Randomized, placebo-controlled clinical trial of an aerosolized ß2-agonist for treatment of acute lung injury.
  297. Physiology, reductionism, and translational medicine: the right mix.
  298. Clinical review: Thinking outside the box--an iconoclastic view of current practice.
  299. Claudin-4 levels are associated with intact alveolar fluid clearance in human lungs.
  300. Advancing donor management research: design and implementation of a large, randomized, placebo-controlled trial.
  301. Clinical significance of elevated B-type natriuretic peptide in patients with acute lung injury with or without right ventricular dilatation: an observational cohort study.
  302. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors.
  303. Positive fluid balance is associated with higher mortality and prolonged mechanical ventilation in pediatric patients with acute lung injury.
  304. Mesenchymal stem cells and acute lung injury.
  305. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals.
  306. Con: corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia.
  307. Decreased respiratory system compliance on the sixth day of mechanical ventilation is a predictor of death in patients with established acute lung injury.
  308. Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis.
  309. Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury.
  310. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury.
  311. Active and passive cigarette smoking and acute lung injury after severe blunt trauma.
  312. Vascular pedicle width in acute lung injury: correlation with intravascular pressures and ability to discriminate fluid status.
  313. Role of CFTR expressed by neutrophils in modulating acute lung inflammation and injury in mice.
  314. Informed consent in research to improve the number and quality of deceased donor organs.
  315. Single-nucleotide polymorphisms in the ß-adrenergic receptor genes are associated with lung allograft utilization.
  316. Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells.
  317. Neuregulin-1-human epidermal receptor-2 signaling is a central regulator of pulmonary epithelial permeability and acute lung injury.
  318. Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients.
  319. The acute respiratory distress syndrome: pathogenesis and treatment.
  320. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.
  321. Stem cells in sepsis and acute lung injury.
  322. The utility of clinical predictors of acute lung injury: towards prevention and earlier recognition.
  323. Priming with endotoxin increases acute lung injury in mice by enhancing the severity of lung endothelial injury.
  324. Mesenchymal stem cells for acute lung injury: preclinical evidence.
  325. Therapeutic potential of mesenchymal stem cells for severe acute lung injury.
  326. Thinking outside the box: Introduction.
  327. The influence of race on the development of acute lung injury in trauma patients.
  328. Pathophysiology of transfusion-related acute lung injury.
  329. Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients.
  330. Assessing the quantity of pulmonary edema in critically ill children.
  331. Advances and challenges in translating stem cell therapies for clinical diseases.
  332. Alveolar fluid clearance is faster in women with acute lung injury compared to men.
  333. Acute lung injury: epidemiology, pathogenesis, and treatment.
  334. Acute respiratory distress syndrome after surgery: can the risk be decreased?
  335. Therapeutic strategies for severe acute lung injury.
  336. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1.
  337. Age-, sex-, and race-based differences among patients enrolled versus not enrolled in acute lung injury clinical trials.
  338. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock.
  339. Update on acute lung injury and critical care medicine 2009.
  340. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis.
  341. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.
  342. Regulated gene expression in cultured type II cells of adult human lung.
  343. Activation of the stress protein response inhibits the STAT1 signalling pathway and iNOS function in alveolar macrophages: role of Hsp90 and Hsp70.
  344. Simulation of lung alveolar epithelial wound healing in vitro.
  345. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury.
  346. Clinical immunology: Culprits with evolutionary ties.
  347. Measuring the quantity of pulmonary edema in clinical lung injury.
  348. Thirty years of critical care medicine.
  349. Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
  350. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia: delivering the secretome.
  351. Requisite role of the cholinergic alpha7 nicotinic acetylcholine receptor pathway in suppressing Gram-negative sepsis-induced acute lung inflammatory injury.
  352. Laminin gamma2 fragments are increased in the circulation of patients with early phase acute lung injury.
  353. Early elevations in B-type natriuretic peptide levels are associated with poor clinical outcomes in pediatric acute lung injury.
  354. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury.
  355. Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury.
  356. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury.
  357. Potential application of mesenchymal stem cells in acute lung injury.
  358. Determining the aetiology of pulmonary oedema by the oedema fluid-to-plasma protein ratio.
  359. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung.
  360. Serotonin decreases alveolar epithelial fluid transport via a direct inhibition of the epithelial sodium channel.
  361. Comparison of two non-bronchoscopic methods for evaluating inflammation in patients with acute hypoxaemic respiratory failure.
  362. NADPH oxidase-1 plays a crucial role in hyperoxia-induced acute lung injury in mice.
  363. Measurement of extravascular lung water using the single indicator method in patients: research and potential clinical value.
  364. Clara cell protein CC16. A new lung epithelial biomarker for acute lung injury.
  365. Inhaled activated protein C: a novel therapy for acute lung injury?
  366. Protective mechanisms of activated protein C in severe inflammatory disorders.
  367. 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia.
  368. Blood product transfusions and clinical outcomes in pediatric patients with acute lung injury.
  369. Higher pulmonary dead space may predict prolonged mechanical ventilation after cardiac surgery.
  370. Recent trends in acute lung injury mortality: 1996-2005.
  371. Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury.
  372. Mesenchymally "stemming" angiogenesis.
  373. Neutrophil sandwiches injure the microcirculation.
  374. Role of protease activated receptor 2 in experimental acute lung injury and lung fibrosis.
  375. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.
  376. A computational approach to understand in vitro alveolar morphogenesis.
  377. The pathogenetic and prognostic value of biologic markers in acute lung injury.
  378. Identification of early acute lung injury at initial evaluation in an acute care setting prior to the onset of respiratory failure.
  379. The role of angiotensin-converting enzyme inhibition in endotoxin-induced lung injury in rats.
  380. Racial and ethnic disparities in mortality from acute lung injury.
  381. Anti-chemokine autoantibody:chemokine immune complexes activate endothelial cells via IgG receptors.
  382. Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid mediates protective effects through regulation of the ERK pathway.
  383. Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs.
  384. Beyond fishing: the role of discovery proteomics in mechanistic lung research.
  385. Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury.
  386. Reasons for nonenrollment in a clinical trial of acute lung injury.
  387. Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury.
  388. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury.
  389. Predictors of mortality in acute lung injury during the era of lung protective ventilation.
  390. Randomized clinical trial of activated protein C for the treatment of acute lung injury.
  391. Alterations in the proteome of pulmonary alveolar type II cells in the rat after hepatic ischemia-reperfusion.
  392. CD47 deficiency protects mice from lipopolysaccharide-induced acute lung injury and Escherichia coli pneumonia.
  393. Novel molecular strategy to prevent pulmonary edema.
  394. Measurement of extravascular lung water in patients with pulmonary edema.
  395. Protein C as a surrogate end-point for clinical trials of sepsis.
  396. Treatment of acute lung injury: clinical and experimental studies.
  397. Aerosolized beta-adrenergic agonist therapy reduces pulmonary edema following lung surgery.
  398. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury.
  399. Bone marrow-derived cells participate in stromal remodeling of the lung following acute bacterial pneumonia in mice.
  400. A framework and mechanistically focused, in silico method for enabling rational translational research.
  401. Beta2 adrenergic agonist therapy may enhance alveolar epithelial repair in patients with acute lung injury.
  402. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity.
  403. Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms.
  404. Advances in critical care for the nephrologist: acute lung injury/ARDS.
  405. Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors.
  406. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury.
  407. Lung epithelial cells induce endodermal differentiation in mouse mesenchymal bone marrow stem cells by paracrine mechanism.
  408. The role of protein C in sepsis.
  409. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders.
  410. Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade.
  411. Rac1 is required for reorientation of polarity and lumen formation through a PI 3-kinase-dependent pathway.
  412. Evidence of temporary airway epithelial repopulation and rare clonal formation by BM-derived cells following naphthalene injury in mice.
  413. Surfactant treatment of aspiration-induced lung injury in children.
  414. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice.
  415. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome.
  416. Workshop summary: phosgene-induced pulmonary toxicity revisited: appraisal of early and late markers of pulmonary injury from animal models with emphasis on human significance.
  417. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation.
  418. Pulmonary barriers to pneumonia and sepsis.
  419. Acute lung injury edema fluid decreases net fluid transport across human alveolar epithelial type II cells.
  420. Pulmonary dead space fraction and pulmonary artery systolic pressure as early predictors of clinical outcome in acute lung injury.
  421. Alveolar edema fluid clearance and acute lung injury.
  422. Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils.
  423. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?
  424. MAPK pathway mediates EGR-1-HSP70-dependent cigarette smoke-induced chemokine production.
  425. Genomics and proteomics of lung disease: conference summary.
  426. Activation of the alpha7 nAChR reduces acid-induced acute lung injury in mice and rats.
  427. Postobstructive pulmonary edema: a case for hydrostatic mechanisms.
  428. Impact of low and high tidal volumes on the rat alveolar epithelial type II cell proteome.
  429. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor.
  430. Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs.
  431. Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation.
  432. Formation of cysts by alveolar type II cells in three-dimensional culture reveals a novel mechanism for epithelial morphogenesis.
  433. Nonventilatory treatments for acute lung injury and ARDS.
  434. Pathogenetic significance of biological markers of ventilator-associated lung injury in experimental and clinical studies.
  435. Pulmonary artery catheter and fluid management in acute lung injury and the acute respiratory distress syndrome.
  436. Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts.
  437. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation.
  438. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death.
  439. Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury.
  440. Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function.
  441. Protein permeability in lung injury: now in real time again?
  442. Treatment of acute lung injury: historical perspective and potential future therapies.
  443. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury.
  444. Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats.
  445. Acute lung injury and the coagulation pathway: Potential role of gene polymorphisms in the protein C and fibrinolytic pathways.
  446. Beta-2-agonist treatment as a potential therapy for acute inhalational lung injury.
  447. Sepsis and stretch: synergistic effects on alveolar epithelial cell death?
  448. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury.
  449. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury.
  450. Higher urine desmosine levels are associated with mortality in patients with acute lung injury.
  451. Integrating acute lung injury and regulation of alveolar fluid clearance.
  452. Evolving practices in critical care and potential implications for management of acute kidney injury.
  453. Extracellular heat shock protein 72 is a marker of the stress protein response in acute lung injury.
  454. Airway epithelium, inflammation, and mechanisms of disease: A tribute to Carol B. Basbaum.
  455. Animal models of transfusion-related acute lung injury.
  456. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
  457. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury.
  458. Perspectives, translational research, and letters to the editor.
  459. Alveolar epithelial ion and fluid transport: recent progress.
  460. Clinical trial design--effect of prone positioning on clinical outcomes in infants and children with acute respiratory distress syndrome.
  461. Stimulation of alveolar epithelial fluid clearance in human lungs by exogenous epinephrine.
  462. Warm ischemia-induced alterations in oxidative and inflammatory proteins in hepatic Kupffer cells in rats.
  463. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury.
  464. Beta-adrenergic agonist therapy as a potential treatment for acute lung injury.
  465. Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury.
  466. Biological markers of lung injury before and after the institution of positive pressure ventilation in patients with acute lung injury.
  467. Clinical practice. Acute pulmonary edema.
  468. TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK.
  469. Protective effect of endogenous beta-adrenergic tone on lung fluid balance in acute bacterial pneumonia in mice.
  470. Therapeutic value of a lung protective ventilation strategy in acute lung injury.
  471. Congenital diaphragmatic hernia prevents absorption of distal air space fluid in late-gestation rat fetuses.
  472. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management.
  473. High prevalence of pulmonary arterial thrombi in donor lungs rejected for transplantation.
  474. Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells.
  475. Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms.
  476. Leukotrienes in acute lung injury: a potential therapeutic target?
  477. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial.
  478. VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema.
  479. Recent advances in mechanical ventilation.
  480. Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells.
  481. Accuracy of physiologic dead space measurements in patients with acute respiratory distress syndrome using volumetric capnography: comparison with the metabolic monitor method.
  482. Decreased expression of both the alpha1- and alpha2-subunits of the Na-K-ATPase reduces maximal alveolar epithelial fluid clearance.
  483. Critical care in AJRCCM 2004.
  484. Interleukin-1beta decreases expression of the epithelial sodium channel alpha-subunit in alveolar epithelial cells via a p38 MAPK-dependent signaling pathway.
  485. In vitro and in vivo regulation of transepithelial lung alveolar sodium transport by serine proteases.
  486. Acute effects of tidal volume strategy on hemodynamics, fluid balance, and sedation in acute lung injury.
  487. Alveolar epithelium: role in lung fluid balance and acute lung injury.
  488. Differential effects of sustained inflation recruitment maneuvers on alveolar epithelial and lung endothelial injury.
  489. Is there a role for beta-adrenoceptor agonists in the management of acute lung injury and the acute respiratory distress syndrome?
  490. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury.
  491. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis.
  492. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality.
  493. Integrated control of lung fluid balance.
  494. HO-1 induction restores c-AMP-dependent lung epithelial fluid transport following severe hemorrhage in rats.
  495. Can nicotine treat sepsis?
  496. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury.
  497. Acute lung injury and acute respiratory distress syndrome in pregnancy.
  498. Direct visual instillation as a method for efficient delivery of fluid into the distal airspaces of anesthetized mice.
  499. Prognostic value of the pulmonary dead-space fraction during the first 6 days of acute respiratory distress syndrome.
  500. Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock.
  501. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome.
  502. Hydrostatic mechanisms may contribute to the pathogenesis of human re-expansion pulmonary edema.
  503. Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury.
  504. Coagulation-dependent mechanisms and asthma.
  505. Proteomics: current techniques and potential applications to lung disease.
  506. Transfusion-related acute lung injury: a review.
  507. Bench-to-bedside review: the role of the alveolar epithelium in the resolution of pulmonary edema in acute lung injury.
  508. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury.
  509. Plasma protein C levels in patients with acute lung injury: prognostic significance.
  510. H(2)O(2) inhibits alveolar epithelial wound repair in vitro by induction of apoptosis.
  511. Mechanisms of alveolar protein clearance in the intact lung.
  512. Diagnostic utility of B-type natriuretic peptide in patients with acute dyspnea or pleural effusions.
  513. Fluid transport across cultured rat alveolar epithelial cells: a novel in vitro system.
  514. Malnutrition impairs alveolar fluid clearance in rat lungs.
  515. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression.
  516. Look before you leap: how do intensivists improve care for critically ill patients?
  517. Why does acute lung injury have no impact on mortality in patients with major trauma?
  518. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha.
  519. Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury.
  520. Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury.
  521. Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs.
  522. The ADP ribosyltransferase domain of Pseudomonas aeruginosa ExoT contributes to its biological activities.
  523. Cytokine-mediated inflammation in acute lung injury.
  524. Pancreatitis-associated acute lung injury: new insights.
  525. Transforming growth factor-beta 1 regulates lung epithelial barrier function and fluid transport.
  526. Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury.
  527. Effects of recruitment maneuvers in patients with acute lung injury and acute respiratory distress syndrome ventilated with high positive end-expiratory pressure.
  528. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury.
  529. Effect of continuous hemofiltration on hemodynamics, lung inflammation and pulmonary edema in a canine model of acute lung injury.
  530. Acute lung injury and the acute respiratory distress syndrome.
  531. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome.
  532. Pulmonary edema fluid antioxidants are depressed in acute lung injury.
  533. Transforming growth factor-beta induces fibrosis in immune cell-depleted lungs.
  534. Transforming growth factor-beta1 decreases expression of the epithelial sodium channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism.
  535. Functional identification of the alveolar edema reabsorption activity of murine tumor necrosis factor-alpha.
  536. Early elevation of plasma soluble intercellular adhesion molecule-1 in pediatric acute lung injury identifies patients at increased risk of death and prolonged mechanical ventilation.
  537. Protein C and thrombomodulin in human acute lung injury.
  538. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury.
  539. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group.
  540. Therapeutic strategies to hasten the resolution of pulmonary edema.
  541. Prevention of ventilator-associated pneumonia: an evidence-based systematic review.
  542. Keratinocyte growth factor promotes cell motility during alveolar epithelial repair in vitro.
  543. High tidal volume ventilation induces NOS2 and impairs cAMP- dependent air space fluid clearance.
  544. Prognostic value of surfactant proteins A and D in patients with acute lung injury.
  545. Alveolar fluid clearance in patients with ARDS: does it make a difference?
  546. Clinical measurement of pulmonary edema.
  547. Lung edema clearance: 20 years of progress: invited review: alveolar edema fluid clearance in the injured lung.
  548. Meta-analysis of acute lung injury and acute respiratory distress syndrome trials.
  549. Alveolar epithelial fluid transport in acute lung injury: new insights.
  550. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome.
  551. Hypoxia upregulates VEGF expression in alveolar epithelial cells in vitro and in vivo.
  552. Selected contribution: long-term effects of beta(2)-adrenergic receptor stimulation on alveolar fluid clearance in mice.
  553. Selected contribution: mechanisms that may stimulate the resolution of alveolar edema in the transplanted human lung.
  554. Measuring microvascular blood flow in sepsis--a continuing challenge.
  555. Science review: mechanisms of ventilator-induced injury.
  556. Hypoxia and beta 2-agonists regulate cell surface expression of the epithelial sodium channel in native alveolar epithelial cells.
  557. Central line infections.
  558. Invited review: Active fluid clearance from the distal air spaces of the lung.
  559. Time-dependent effect of pneumonectomy on alveolar epithelial fluid clearance in rat lungs.
  560. Ventilator-induced lung injury: in vivo and in vitro mechanisms.
  561. Pleural surface fluorescence measurement of Na+ and Cl- transport across the air space-capillary barrier.
  562. Assessment of lungs rejected for transplantation and implications for donor selection.
  563. The pulmonary epithelium is an important mediator of ventilator-induced lung injury.
  564. Evidence against aquaporin-1-dependent CO2 permeability in lung and kidney.
  565. Keratinocyte growth factor can enhance alveolar epithelial repair by nonmitogenic mechanisms.
  566. Lung epithelial fluid transport and the resolution of pulmonary edema.
  567. Enhancing the safety of critically ill patients by reducing urinary and central venous catheter-related infections.
  568. Aerosolized beta(2)-adrenergic agonists achieve therapeutic levels in the pulmonary edema fluid of ventilated patients with acute respiratory failure.
  569. Activity of pulmonary edema fluid interleukin-8 bound to alpha(2)-macroglobulin in patients with acute lung injury.
  570. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair.
  571. The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology.
  572. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome.
  573. Airway pressures and early barotrauma in patients with acute lung injury and acute respiratory distress syndrome.
  574. Clinical Acute Lung Injury and Acute Respiratory Distress Syndrome.
  575. Distal air space epithelial fluid clearance in near-term rat fetuses is fast and requires endogenous catecholamines.
  576. Microarray analysis indicates that pulmonary edema fluid from patients with acute lung injury mediates inflammation, mitogen gene expression, and fibroblast proliferation through bioactive interleukin-1.
  577. Lidocaine induces a reversible decrease in alveolar epithelial fluid clearance in rats.
  578. Novel role for CFTR in fluid absorption from the distal airspaces of the lung.
  579. Low tidal volume reduces epithelial and endothelial injury in acid-injured rat lungs.
  580. Stress preconditioning attenuates oxidative injury to the alveolar epithelium of the lung following haemorrhage in rats.
  581. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury.
  582. Clinicians' approaches to mechanical ventilation in acute lung injury and ARDS.
  583. Hypoxia reduces alveolar epithelial sodium and fluid transport in rats: reversal by beta-adrenergic agonist treatment.
  584. Keratinocyte growth factor reduces alveolar epithelial susceptibility to in vitro mechanical deformation.
  585. Targeted transgenic expression of beta(2)-adrenergic receptors to type II cells increases alveolar fluid clearance.
  586. The Role of Protein C in Sepsis.
  587. Treatment of ARDS.
  588. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome.
  589. Beta1-adrenoceptor stimulation by high-dose terbutaline downregulates terbutaline-stimulated alveolar fluid clearance in ex vivo rat lung.
  590. Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide.
  591. Rapid alveolar epithelial fluid clearance following lung lavage in pulmonary alveolar proteinosis.
  592. Mechanisms of TNF-alpha stimulation of amiloride-sensitive sodium transport across alveolar epithelium.
  593. Role of aquaporin water channels in airway fluid transport, humidification, and surface liquid hydration.
  594. TGF-beta is a critical mediator of acute lung injury.
  595. Reactive nitrogen species inhibit alveolar epithelial fluid transport after hemorrhagic shock in rats.
  596. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome.
  597. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism.
  598. Contribution of amiloride-insensitive pathways to alveolar fluid clearance in adult rats.
  599. Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair.
  600. Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties.
  601. Alveolar epithelial transport. Basic science to clinical medicine.
  602. Denopamine, a beta(1)-adrenergic agonist, increases alveolar fluid clearance in ex vivo rat and guinea pig lungs.
  603. Etiology of acute pulmonary edema during liver transplantation : a series of cases with analysis of the edema fluid.
  604. Increased levels of nitrate and surfactant protein a nitration in the pulmonary edema fluid of patients with acute lung injury.
  605. Transepithelial sodium and water transport in the lung. Major player and novel therapeutic target in pulmonary edema.
  606. Interleukin-1beta augments in vitro alveolar epithelial repair.
  607. Role of aquaporin water channels in pleural fluid dynamics.
  608. Beta-adrenergic agonist therapy accelerates the resolution of hydrostatic pulmonary edema in sheep and rats.
  609. Alveolar epithelial barrier. Role in lung fluid balance in clinical lung injury.
  610. Relationship of interstitial fluid volume to alveolar fluid clearance in mice: ventilated vs. in situ studies.
  611. Diabetes mellitus: a negative predictor for the development of acute respiratory distress syndrome from septic shock.
  612. Role of aquaporins in alveolar fluid clearance in neonatal and adult lung, and in oedema formation following acute lung injury: studies in transgenic aquaporin null mice.
  613. Cost-effectiveness of noninvasive ventilation for acute chronic obstructive pulmonary disease: cashing in too quickly.
  614. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema.
  615. Lung deflation impairs alveolar epithelial fluid transport in ischemic rabbit and rat lungs.
  616. The acute respiratory distress syndrome.
  617. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.
  618. Aquaporin water channels and lung physiology.
  619. Hypoxia regulates gene expression of alveolar epithelial transport proteins.
  620. [Amiloride-sensitive sodium channel in the nephron and its activation by vasopressin].
  621. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance.
  622. A novel alveolar type I cell-specific biochemical marker of human acute lung injury.
  623. Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation.
  624. Dexamethasone and thyroid hormone pretreatment upregulate alveolar epithelial fluid clearance in adult rats.
  625. Carbon dioxide permeability of aquaporin-1 measured in erythrocytes and lung of aquaporin-1 null mice and in reconstituted proteoliposomes.
  626. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation.
  627. Early expression of beta- and gamma-subunits of epithelial sodium channel during human airway development.
  628. Initial severity of metabolic acidosis predicts the development of acute lung injury in severely traumatized patients.
  629. Lung fluid transport in aquaporin-5 knockout mice.
  630. Noninvasive ventilation for acute respiratory failure.
  631. Role of aquaporin-4 in airspace-to-capillary water permeability in intact mouse lung measured by a novel gravimetric method.
  632. Exacerbation of acute pulmonary edema during assisted mechanical ventilation using a low-tidal volume, lung-protective ventilator strategy.
  633. Health-related quality of life after acute lung injury.
  634. Acid-induced lung injury. Protective effect of anti-interleukin-8 pretreatment on alveolar epithelial barrier function in rabbits.
  635. Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy.
  636. Interleukin-8 mediates injury from smoke inhalation to both the lung endothelial and the alveolar epithelial barriers in rabbits.
  637. Interobserver variability in applying a radiographic definition for ARDS.
  638. Alveolar epithelial fluid transport and the resolution of clinically severe hydrostatic pulmonary edema.
  639. The lectin-like domain of tumor necrosis factor-alpha increases membrane conductance in microvascular endothelial cells and peritoneal macrophages.
  640. alpha-adrenergic blockade restores normal fluid transport capacity of alveolar epithelium after hemorrhagic shock.
  641. Indomethacin does not influence alveolar liquid clearance in anesthetized sheep or rats.
  642. Oxidant-mediated lung injury in the acute respiratory distress syndrome.
  643. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response.
  644. Alveolar epithelial fluid transport can be upregulated simultaneously in rats by two different mechanisms.
  645. Conference summary: acute lung injury.
  646. Elevated pulmonary edema fluid concentrations of soluble intercellular adhesion molecule-1 in patients with acute lung injury: biological and clinical significance.
  647. HTI56, an integral apical membrane protein of the human alveolar type I cell, is a biochemical marker of acute lung injury.
  648. Inhibition of beta-adrenergic-dependent alveolar epithelial clearance by oxidant mechanisms after hemorrhagic shock.
  649. Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation.
  650. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.
  651. Lung fluid transport in aquaporin-1 and aquaporin-4 knockout mice.
  652. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome.
  653. Alveolar epithelial fluid clearance persists in the presence of moderate left atrial hypertension in sheep.
  654. Ischemia-reperfusion lung injury in rabbits: mechanisms of injury and protection.
  655. Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice.
  656. Role of collagenase in mediating in vitro alveolar epithelial wound repair.
  657. Risk reduction in the intensive care unit.
  658. Alveolar epithelial fluid transport: basic mechanisms and clinical relevance.
  659. Pulmonary edema in obstetric patients is rapidly resolved except in the presence of infection or of nitroglycerin tocolysis after open fetal surgery.
  660. Upregulation of alveolar epithelial fluid transport after subacute lung injury in rats from bleomycin.
  661. Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance.
  662. Protective ventilation for the acute respiratory distress syndrome.
  663. A mouse model to test the in vivo efficacy of chemical chaperones.
  664. Effects of ATP-sensitive potassium channel opener on potassium transport and alveolar fluid clearance in the resected human lung.
  665. Evidence against a role of mouse, rat, and two cloned human t1alpha isoforms as a water channel or a regulator of aquaporin-type water channels.
  666. New in situ mouse model to quantify alveolar epithelial fluid clearance.
  667. High microvascular endothelial water permeability in mouse lung measured by a pleural surface fluorescence method.
  668. The American-European Consensus Conference on ARDS, part 2. Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling.
  669. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome.
  670. Highly water-permeable type I alveolar epithelial cells confer high water permeability between the airspace and vasculature in rat lung.
  671. Just say NO to inhaled nitric oxide for the acute respiratory distress syndrome.
  672. Developmental changes in water permeability across the alveolar barrier in perinatal rabbit lung.
  673. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance.
  674. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation.
  675. Upregulation of alveolar liquid clearance after fluid resuscitation for hemorrhagic shock in rats.
  676. Inhibition of CD18 or CD11b attenuates acute lung injury after acid instillation in rabbits.
  677. Noninvasive positive pressure ventilation for acute respiratory failure: underutilized or overrated?
  678. Alveolar epithelial fluid clearance mechanisms are intact after moderate hyperoxic lung injury in rats.
  679. Evidence for a hydrostatic mechanism in human neurogenic pulmonary edema.
  680. Protein tyrosine phosphatases mediate cell readhesion in alveolar epithelial cells mechanically separated from in vitro matrix.
  681. Biological markers of acute lung injury: prognostic and pathogenetic significance.
  682. Soluble transforming growth factor-alpha is present in the pulmonary edema fluid of patients with acute lung injury.
  683. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs.
  684. Acute bacterial pneumonia in rats increases alveolar epithelial fluid clearance by a tumor necrosis factor-alpha-dependent mechanism.
  685. Increased alveolar fluid clearance following thoracotomy: report of a case and results of an analysis.
  686. Sharp increase in rat lung water channel expression in the perinatal period.
  687. Soluble and insoluble fibronectin increases alveolar epithelial wound healing in vitro.
  688. Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome.
  689. Increased interleukin-8 concentrations in the pulmonary edema fluid of patients with acute respiratory distress syndrome from sepsis.
  690. Transalveolar osmotic and diffusional water permeability in intact mouse lung measured by a novel surface fluorescence method.
  691. Acid aspiration induced lung injury. New insights and therapeutic options.
  692. Alveolar liquid clearance is increased by endogenous catecholamines in hemorrhagic shock in rats.
  693. Transforming growth factor-alpha increases alveolar liquid clearance in anesthetized ventilated rats.
  694. The acute respiratory distress syndrome.
  695. Alveolar epithelial clearance of protein.
  696. Preservation of alveolar epithelial fluid transport mechanisms in rewarmed human lung after severe hypothermia.
  697. Pulmonary edema in a woman following fetal surgery.
  698. Salt and water transport across alveolar and distal airway epithelia in the adult lung.
  699. Transepithelial water permeability in microperfused distal airways. Evidence for channel-mediated water transport.
  700. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity.
  701. Alveolar endotoxin increases alveolar liquid clearance in rats.
  702. Identification of patients with acute lung injury. Predictors of mortality.
  703. Cellular uptake of albumin from lungs of anesthetized rabbits.
  704. Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms.
  705. Evaluation of definitions of ARDS.
  706. Resistance of the alveolar epithelium to injury from septic shock in sheep.
  707. Death and other complications of emergency airway management in critically ill adults. A prospective investigation of 297 tracheal intubations.
  708. Frequency and importance of barotrauma in 100 patients with acute lung injury.
  709. Fibrosing alveolitis in the adult respiratory distress syndrome.
  710. The effect of salt water on alveolar epithelial barrier function.
  711. Transforming growth factor-alpha enhances alveolar epithelial cell repair in a new in vitro model.
  712. Alveolar fluid clearance in the resected human lung.
  713. Stimulation of lung epithelial liquid clearance by endogenous release of catecholamines in septic shock in anesthetized rats.
  714. Alveolar liquid and protein clearance in anesthetized ventilated rats.
  715. Transcellular water transport in lung alveolar epithelium through mercury-sensitive water channels.
  716. Effect of endocytosis inhibitors on alveolar clearance of albumin, immunoglobulin G, and SP-A in rabbits.
  717. Function of the alveolar epithelial barrier under pathologic conditions.
  718. Molecular cloning of a mercurial-insensitive water channel expressed in selected water-transporting tissues.
  719. Prevalence and severity of neurologic dysfunction in critically ill patients. Influence on need for continued mechanical ventilation.
  720. Alveolar epithelial barrier and acute lung injury.
  721. Transient effect of epidermal growth factor on the motility of an immortalized mammary epithelial cell line.
  722. Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits.
  723. Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.
  724. Effect of temperature on alveolar liquid and protein clearance in an in situ perfused goat lung.
  725. Neutrophil-activating peptide-2 in patients with pulmonary edema from congestive heart failure or ARDS.
  726. Preoperative and intraoperative factors associated with prolonged mechanical ventilation. A study in patients following major abdominal vascular surgery.
  727. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock.
  728. Alveolar liquid and protein clearance in the absence of blood flow or ventilation in sheep.
  729. Clearance of different-sized proteins from the alveolar space in humans and rabbits.
  730. Neuropeptides in pulmonary edema fluid of adult respiratory distress syndrome.
  731. Pulmonary edema associated with salt water near-drowning: new insights.
  732. Persistent paralysis in critically ill patients after long-term administration of vecuronium.
  733. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality.
  734. Obstetric patients requiring critical care. A five-year review.
  735. Effect of epinephrine on the ability of end-tidal carbon dioxide readings to predict initial resuscitation from cardiac arrest.
  736. Alveolar and lung liquid clearance in the absence of pulmonary blood flow in sheep.
  737. Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin.
  738. Critical care medicine.
  739. Alveolar and lung liquid clearance in anesthetized rabbits.
  740. Resolution of pulmonary edema. New insights.
  741. Right-heart catheterization is a diagnostic procedure not a therapeutic intervention.
  742. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans.
  743. Pulmonary endothelial cell injury and altered lung metabolic function. Early detection of the adult respiratory distress syndrome and possible functional significance.
  744. The adult respiratory distress syndrome. Definition and prognosis.
  745. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome.
  746. The adult respiratory distress syndrome: definition and prognosis, pathogenesis and treatment.
  747. Comparison of transesophageal echocardiographic and scintigraphic estimates of left ventricular end-diastolic volume index and ejection fraction in patients following coronary artery bypass grafting.
  748. The case for oxidants in the adult respiratory distress syndrome--"elementary, Dr. Watson".
  749. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients.
  750. Pulmonary manifestations of endocrine and metabolic disorders.
  751. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability.
  752. Protein clearance from the air spaces and lungs of unanesthetized sheep over 144 h.
  753. New modes of mechanical ventilation for ARDS. How should they be evaluated?
  754. Respiratory management after cardiac surgery.
  755. The adult respiratory distress syndrome. New insights into diagnosis, pathophysiology, and treatment.
  756. Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance.
  757. Bedside catheterization of the pulmonary artery: risks compared with benefits.
  758. Relationship of pleural effusions to increased permeability pulmonary edema in anesthetized sheep.
  759. An expanded definition of the adult respiratory distress syndrome.
  760. Alveolar liquid and protein clearance from normal dog lungs.
  761. Hydrostatic versus increased permeability pulmonary edema: diagnosis based on radiographic criteria in critically ill patients.
  762. Sulfidopeptide-leukotriene peptidases in pulmonary edema fluid from patients with the adult respiratory distress syndrome.
  763. Pleural effusions associated with hydrostatic and increased permeability pulmonary edema.
  764. Lack of association of pleural effusion with chronic pulmonary arterial and right atrial hypertension.
  765. Adult respiratory distress syndrome related to antilymphocyte globulin therapy.
  766. Beta-adrenergic agonists increase lung liquid clearance in anesthetized sheep.
  767. The adult respiratory distress syndrome.
  768. Helium-oxygen gas therapy. Use and availability for the emergency treatment of inoperable airway obstruction.
  769. Central intravascular pressure measurements: when should we believe them?
  770. Pathophysiology of the adult respiratory distress syndrome. What have we learned from human studies?
  771. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery.
  772. Clinical spectrum of pulmonary mucormycosis.
  773. Leukotrienes in pulmonary edema fluid after cardiopulmonary bypass.
  774. Intensive care unit: how stressful for physicians?
  775. Relationship of pleural effusions to pulmonary hemodynamics in patients with congestive heart failure.
  776. Cellular basis for injury and repair in the adult respiratory distress syndrome.
  777. Long-term clearance of liquid and protein from the lungs of unanesthetized sheep.
  778. Pathophysiology of pulmonary edema.
  779. Resolution of pulmonary edema. Mechanisms of liquid, protein, and cellular clearance from the lung.
  780. Undrained bloody pericardial effusion in the early postoperative period after coronary bypass surgery: a prospective blood pool study.
  781. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome.
  782. Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome.
  783. Neurogenic pulmonary edema.
  784. Morphologic and physiologic correlates of increased extravascular lung water.
  785. Cardiovascular-pulmonary monitoring in the intensive care unit (Part 2).
  786. Cardiovascular-pulmonary monitoring in the intensive care unit (Part 1).
  787. Guillain-Barré syndrome: psychosocial aspects of management.
  788. Hemodynamic management in the adult respiratory distress syndrome.
  789. Invasive hemodynamic monitoring in critically ill patients.
  790. Overperfusion, hypoxia, and increased pressure cause only hydrostatic pulmonary edema in anesthetized sheep.
  791. Differential liquid and protein clearance from the alveoli of anesthetized sheep.
  792. Adult respiratory distress syndrome complicating diabetic ketoacidosis.
  793. Anatomic variations of efferent duct from caudal mediastinal lymph node in sheep.
  794. Chest mass with pleurisy.
  795. Thyrotoxicosis: comparison of effects of thyroid ablation and beta-adrenergic blockade on metabolic rate and ventilatory control.
  796. Acute pseudogout in the absence of synovial fluid Leukocytes.
  797. Hypertrophic osteoarthropathy in adults with cystic fibrosis.
  798. Grand mal seizure induced by oral theophylline.